Immunodiagnostic trims jobs as sales slump in the past year

Immunodiagnostic Systems' fully automated system for lab and clinic tests
Immunodiagnostic Systems' fully automated IDS-iSYS Multi- Discipline Automated System

British laboratory and clinic testing kit maker Immunodiagnostic Systems says slumping sales have cost 31 jobs at its Boldon manufacturing facility over the past 12 months.

In its full-year trading update, the company said full-year sales for the 12 months ended March 31 fell 13% to about £39 million ($57 million). The company, which makes both manual and automated testing kits, said the losses were mostly due to sluggish sales in its manual assay business where test volumes continue to move toward automated solutions where there is more competition, the Chronicle reported.

Immunodiagnostic reported a total of 315 employees on a full time basis, which is down 31 from a year ago.

Survey

Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

The company has manufacturing facilities in Boldon and Italy, as well as an instrument production and system engineering in France and a manufacturing facility in Liege, Belgium.

The declines in sales are expected to last through this year.

- check out the Chronicle story

Related Articles:
Embark Veterinary launches DNA testing kit for dogs
European investor shells out $118M for DNA testing outfit to boost animal Dx offerings

Image courtesy of Immunodiagnostic Systems

Read more on

Suggested Articles

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.

Pfizer is ponying up $500 million on top of $100 million already committed to a gene therapy manufacturing facility in North Carolina.